Process development for a key synthetic intermediate of LY2140023, a clinical candidate for the treatment of schizophrenia

…, DW Hoard, ME Laurila, ME LeTourneau…

Index: Waser, Mario; Moher, Eric D.; Borders, Sandy S. K.; Hansen, Marvin M.; Hoard, David W.; Laurila, Michael E.; Letourneau, Michael E.; Miller, Richard D.; Phillips, Michael L.; Sullivan, Kevin A.; Ward, Jeffrey A.; Xie, Chaoyu; Bye, Cheryl A.; Leitner, Tanja; Herzog-Krimbacher, Brigitte; Kordian, Marcus; Muellner, Martin Organic Process Research and Development, 2011 , vol. 15, # 6 p. 1266 - 1274

Full Text: HTML

Citation Number: 8

Abstract

To fuel clinical development of the experimental CNS medicine LY2140023, we developed a scalable route for the multistep synthesis of a pivotal synthetic intermediate. The core of the conformationally restricted glutamic acid-based amino acid analogue was built via a Rh- catalyzed cyclopropanation of thiophene. Regioselective functionalization of the remaining double bond was achieved by a hydroboration/oxidation sequence followed by a ...